Striving for the Chinese government to fight for American drug dealer PfizerThe license allows Chinese pharmaceutical merchants to produce PAXLOVID generic drugs, and Panfield President Albert Bourla has denied the news, but revealed that the company is working with Pfizer's partner in China to prepare to produce PAXLOVID in China in the first half of this year.
Reuters reported on Friday (January 6) that China began to talk about the PAXLOVID generic drugs in China at the end of December last year.The negotiations are led by the China National Drug Administration, and strive to finalize the clause of this license before the Lunar New Year (January 22) this year (January 22).
Comprehensive Reuters and Bloomberg reported that the Morgan Chase Medical Care Conference held at San Francisco on Monday (January 9) denied reports, but revealed that the two parties have signed an agreement to produce PaxLovid in China in China, Pfizer's partner in China is responsible for drug production, and then sold to the Chinese market.
He said that the partner had provided thousands of therapeutic drugs to China last year, and this number has increased to millions in the past few weeks.
Alber did not disclose the name of the partner. It only said that the partner has not yet begun to produce, but it will soon start. It is expected to start selling Paxlovid in China in the first half of this year.
The National Medical Security Bureau said on Sunday (January 8) that the negotiations with Pfizer Pharmaceutical Company's negotiations on the treatment of crown diseases failed to succeed, and PaxLovid failed to include the medical insurance directory because the offer was too high.This means that after March 31, Paxlovid will be removed from the list of Chinese medical insurance directory.
In this regard, Aberle said that the quotation required by China is lower than most low -income countries. "They are the second largest economy in the world.s price".However, he also said that although PaxLovid failed to include the medical insurance directory, it may eventually only sell it to China's private market, but this will not affect the company's business in China.
